SCHEMBL4297399

SCHEMBL4297399

O=C(Nc1nccs1)c1ccc2[nH]ccc2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.64
NPC1 O15118 9/20 0.64
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
MAPT P10636 2/20 0.59
POLB P06746 1/20 0.59
ESR2 Q92731 1/20 0.59
HSD17B10 Q99714 1/20 0.59
SMN1; SMN2 Q16637 3/20 0.56
LMNA P02545 2/20 0.56
RECQL P46063 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MAPK1 P28482 2/20 0.55
ALDH1A1 P00352 1/20 0.55
PIK3CD O00329 1/20 0.55
PIK3C2B O00750 1/20 0.55
AURKA O14965 1/20 0.55
PIK3C2G O75747 1/20 0.55
CDK1 P06493 1/20 0.55
CDK4 P11802 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963854 0.83 RAB9A (0.89) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL15113485 0.83 KMT2A (0.66) MEN1KMT2AMAPTPOLBLMNA
SCHEMBL5413640 0.81 RAB9A (0.63) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL4241715 0.77 RAB9A (0.62) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL7335284 0.75 RAB9A (0.74) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL4241712 0.75 RAB9A (0.59) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL5836059 0.75 CCNE1 (0.59) RAB9ANPC1SMN1; SMN2ALDH1A1CDK1
SCHEMBL2655489 0.75 NR3C1 (0.60) RAB9ANPC1MEN1KMT2AMAPT
Hydrochloric Acid SCHEMBL4079710 0.75 RAB9A (0.69) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL2956673 0.74 RAB9A (0.71) RAB9ANPC1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
CN-1870996-A N-thiazol-2-yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2006-11-29 CN disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885MEN1 3248/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885MEN1 3248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.